Skip to main content
PMC home page
Journal of Medical Ethics logoLink to Journal of Medical Ethics
. 2005 Jan;31(1):2–6. doi: 10.1136/jme.2003.005272

Informed consent should be obtained from patients to use products (skin substitutes) and dressings containing biological material

S Enoch 1, H Shaaban 1, K Dunn 1
PMCID: PMC1734000  PMID: 15634745

Abstract

Background: Biological products (tissue engineered skin, allograft and xenograft, and biological dressings) are widely used in the treatment of burns, chronic wounds, and other forms of acute injury. However, the religious and ethical issues, including consent, arising from their use have never been addressed in the medical literature.

Aims: This study was aimed to ascertain the views of religious leaders about the acceptability of biological products and to evaluate awareness among healthcare professionals about their constituents.

Methods: The religious groups that make up about 75% of the United Kingdom population were identified and a questionnaire on 11 biological products was sent to its leaders. Another questionnaire concerning 17 products (11 biological and 6 synthetic dressings) was sent to 100 healthcare professionals working in seven specialist units in the UK.

Results: All religious leaders (100% response rate) replied, some after consultation with international bodies. Among them, 77% said that patients should be informed of the constituents of the biological products and consent obtained. Some leaders expressed concerns about particular products including the transmission of viral and prion diseases, cruelty to animals, and material derived from neonates. None of the healthcare professionals (73% response rate) surveyed knew the constituents of all the products correctly.

Conclusion: Ignoring religious sensitivities and neglecting consent in the usage of biological products could have very serious implications, including litigation. Hospitals and manufacturers should take immediate measures to enlighten healthcare professionals of the constituents of these products so that they can obtain informed consent from patients.

Full Text

The Full Text of this article is available as a PDF (74.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews N. J., Farrington C. P., Ward H. J. T., Cousens S. N., Smith P. G., Molesworth A. M., Knight R. S. G., Ironside J. W., Will R. G. Deaths from variant Creutzfeldt-Jakob disease in the UK. Lancet. 2003 Mar 1;361(9359):751–752. doi: 10.1016/s0140-6736(03)12632-3. [DOI] [PubMed] [Google Scholar]
  2. Bruce M. E., Will R. G., Ironside J. W., McConnell I., Drummond D., Suttie A., McCardle L., Chree A., Hope J., Birkett C. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature. 1997 Oct 2;389(6650):498–501. doi: 10.1038/39057. [DOI] [PubMed] [Google Scholar]
  3. Dolynchuk K., Hull P., Guenther L., Sibbald R. G., Brassard A., Cooling M., Delorme L., Gulliver W., Bourassa D. H., Ho V. The role of Apligraf in the treatment of venous leg ulcers. Ostomy Wound Manage. 1999 Jan;45(1):34–43. [PubMed] [Google Scholar]
  4. Ersek R. A., Hachen H. J. Porcine xenografts in the treatment of pressure ulcers. Ann Plast Surg. 1980 Dec;5(6):464–470. doi: 10.1097/00000637-198012000-00009. [DOI] [PubMed] [Google Scholar]
  5. Grant I. Ethical issues in burn care. Burns. 1999 Jun;25(4):307–315. doi: 10.1016/s0305-4179(98)00151-x. [DOI] [PubMed] [Google Scholar]
  6. Hansbrough J. F., Franco E. S. Skin replacements. Clin Plast Surg. 1998 Jul;25(3):407–423. [PubMed] [Google Scholar]
  7. Kearney J. N. Clinical evaluation of skin substitutes. Burns. 2001 Aug;27(5):545–551. doi: 10.1016/s0305-4179(01)00020-1. [DOI] [PubMed] [Google Scholar]
  8. Lee K. H. Tissue-engineered human living skin substitutes: development and clinical application. Yonsei Med J. 2000 Dec;41(6):774–779. doi: 10.3349/ymj.2000.41.6.774. [DOI] [PubMed] [Google Scholar]
  9. Maral T., Borman H., Arslan H., Demirhan B., Akinbingol G., Haberal M. Effectiveness of human amnion preserved long-term in glycerol as a temporary biological dressing. Burns. 1999 Nov;25(7):625–635. doi: 10.1016/s0305-4179(99)00072-8. [DOI] [PubMed] [Google Scholar]
  10. McKintosh Edward, Tabrizi Sarah J., Collinge John. Prion diseases. J Neurovirol. 2003 Apr;9(2):183–193. doi: 10.1080/13550280390194082. [DOI] [PubMed] [Google Scholar]
  11. Pruitt B. A., Jr, Curreri P. W. The burn wound and its care. Arch Surg. 1971 Oct;103(4):461–468. doi: 10.1001/archsurg.1971.01350100055010. [DOI] [PubMed] [Google Scholar]
  12. Pruitt B. A., Jr The evolutionary development of biologic dressings and skin substitutes. J Burn Care Rehabil. 1997 Jan-Feb;18(1 Pt 2):S2–S5. doi: 10.1097/00004630-199701001-00002. [DOI] [PubMed] [Google Scholar]
  13. Schiller W. R., Bay R. C., Garren R. L., Parker I., Sagraves S. G. Hyperdynamic resuscitation improves survival in patients with life-threatening burns. J Burn Care Rehabil. 1997 Jan-Feb;18(1 Pt 1):10–16. doi: 10.1097/00004630-199701000-00002. [DOI] [PubMed] [Google Scholar]
  14. Shakespeare Peter, Shakespeare Valerie. Survey: use of skin substitute materials in UK burn treatment centres. Burns. 2002 Jun;28(4):295–297. doi: 10.1016/s0305-4179(02)00062-1. [DOI] [PubMed] [Google Scholar]
  15. Sheridan R. L., Tompkins R. G. Skin substitutes in burns. Burns. 1999 Mar;25(2):97–103. doi: 10.1016/s0305-4179(98)00176-4. [DOI] [PubMed] [Google Scholar]
  16. Wolf D. L., Capozzi A., Pennisi V. R. Evaluation of biological dressings. Ann Plast Surg. 1980 Sep;5(3):186–190. doi: 10.1097/00000637-198009000-00003. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Ethics are provided here courtesy of BMJ Publishing Group

RESOURCES